Thomas Yau

机构：University of Hong Kong

发表论文 4 篇 · 总被引 14 次 · h-index 1

代表论文

• Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. (2026 · Journal of Clinical Oncology · 被引 13)
• Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW. (2026 · Journal of Clinical Oncology · 被引 1)
• Pattern of progression in advanced hepatocellular carcinoma treated with immunotherapy. (2026 · Journal of Clinical Oncology)
• Sequencing fruquintinib and trifluridine/tipiracil to improve outcomes in the real-world management of MMR-proficient, chemo-refractory colorectal cancer in Hong Kong. (2026 · Journal of Clinical Oncology)